IRIS
ALTAVILLA, Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.035
NA - Nord America 4.825
AS - Asia 765
SA - Sud America 8
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 3
AF - Africa 1
Totale 10.641
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.817
IE - Irlanda 1.506
SE - Svezia 1.215
CN - Cina 723
IT - Italia 674
UA - Ucraina 463
DE - Germania 291
GB - Regno Unito 231
FI - Finlandia 199
PL - Polonia 155
BE - Belgio 117
FR - Francia 61
AT - Austria 44
RU - Federazione Russa 37
VN - Vietnam 18
ES - Italia 10
IN - India 9
IR - Iran 9
NL - Olanda 7
CA - Canada 6
BR - Brasile 5
CH - Svizzera 5
AU - Australia 3
NO - Norvegia 3
RO - Romania 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BG - Bulgaria 2
CL - Cile 2
EU - Europa 2
GR - Grecia 2
HR - Croazia 2
LV - Lettonia 2
MX - Messico 2
AL - Albania 1
AM - Armenia 1
CO - Colombia 1
CZ - Repubblica Ceca 1
EE - Estonia 1
HK - Hong Kong 1
HU - Ungheria 1
IQ - Iraq 1
LT - Lituania 1
MM - Myanmar 1
RS - Serbia 1
SC - Seychelles 1
TH - Thailandia 1
TR - Turchia 1
Totale 10.641
Salva come PNG Salva come JPEG
Città #
Dublin 1.506
Chandler 999
Jacksonville 940
Nyköping 687
Beijing 298
Dearborn 251
Ann Arbor 244
Princeton 219
Medford 200
Cambridge 198
Warsaw 155
Des Moines 151
Messina 144
Boardman 115
Brussels 114
Lancaster 110
Jinan 75
Woodbridge 67
Shenyang 51
Wilmington 49
San Mateo 45
Tianjin 39
Vienna 38
Nanjing 34
Houston 33
Hebei 27
Ashburn 26
Zhengzhou 25
Catania 20
Nanchang 20
Rome 19
Haikou 18
Dong Ket 17
Ningbo 17
Norwalk 17
Bremen 15
Scarsdale 15
Changsha 13
Hangzhou 13
Jiaxing 13
Redwood City 13
Seattle 13
Taizhou 13
Leawood 11
Saint Petersburg 10
Helsinki 9
Milan 9
Auburn Hills 8
Guangzhou 8
Modica 8
Fuzhou 7
Taiyuan 7
Augusta 6
Chicago 6
Clearwater 6
London 6
Monmouth Junction 6
Lanzhou 5
Novokuznetsk 5
Vitoria 5
Ardabil 4
Brescia 4
Kemerovo 4
La Spezia 4
Montréal 4
Mumbai 4
Philadelphia 4
Porto Alegre 4
Redmond 4
Tappahannock 4
Atlanta 3
Belpasso 3
Caserta 3
Edinburgh 3
Imola 3
Kunming 3
Las Vegas 3
Los Angeles 3
Mili Marina 3
Napoli 3
New York 3
Northampton 3
Padova 3
Phoenix 3
San Giovanni Rotondo 3
Sassari 3
Savona 3
Sona 3
Aci Castello 2
Albano Laziale 2
Ameno 2
Avezzano 2
Barcelona 2
Bari 2
Brooklyn 2
Cagliari 2
Castelvetrano 2
Domicella 2
Fairfield 2
Florence 2
Totale 7.316
Salva come PNG Salva come JPEG
Nome #
PARAGANGLIOMA MALIGNO DEL CORPO CAROTIDEO.Rilievi Clinici, Morfologici, Istochimici E Ultrastrutturali Su Un Caso. 357
Su di un caso di pseudomyxoma peritonei con diffusione spontanea alla pleura. 122
Should the Use of Surveillance Imaging in Diffuse Large B-Cell Lymphoma Be Discontinued? 98
Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy 98
Liver dysfunction in hcv infected patients with CD20-Positive B-Cell Lymphoma undergoing rituximab combination chemotherapy 88
Studio anatomo-clinico di due casi di sarcoma sinoviale monofasico del ginocchio 84
Epirubucin (EPI) and Paclitaxel (TAX) in advanced breast cancer.a phase II studyi 80
Evaluation of quality of life of patients submitted to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinosis of gastrointestinal and ovarian origin and identification of factors influencing outcome. 80
Amplification and overexpression of the PSMB5 gene contributes to bortezomib resistance in retreatment of patients with multiple myeloma. 80
Increased annual frequency of Hashimoto's thyroiditis between years 1988 and 2007 at a cytological unit of Sicily. 79
EML4-ALK fusion gene in lung adenocarcinoma: A retrospective analysis of the outcome of cisplatin plus pemetrexed treated patients. 77
Apelin beyond kidney failure and hyponatremia: a useful biomarker for cancer disease progression evaluation 77
Applications of genomics in NSCLC 75
Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy 75
Razionale e tecniche della chirurgia citoriduttiva e della chemioipertermia peritoneale. 74
zd1839"iressa" in heavily pretreated patients with advaned/metastatic non-small cell lung cancer(NSCLC):assessment of tolerability and the clinical benefit 73
Myelodysplastic syndrome appearing during imatinib mesylate therapy in a patient with GIST 73
[Serum levels of copper and zinc in patients with lung cancer] 73
Annual increase in the frequency of papillary thyroid carcinoma as diagnosed by fine-needle aspiration at a cytology unit in Sicily. 72
HCV genotype 2 as a risk factor for reactivation in patients with B-cell lymphoma undergoing rituximab combination chemotherapy. 71
Liquid biopsy for lung cancer early detection 71
SUBCUTANEOUS LOW-DOSE ALEMTUZUMAB AS FIRST LINE THERAPY FOR ELDERLY CLL PATIENTS WITH DELETION OF 17p 69
ANALYSES AND DETERMINATION OF LONIDAMINE RELEASE FROM PHARMACEUTICAL FORMULATION. 68
Analytical profile and release of lonidamine from pharmaceutical formulation 68
Bone and lymph node metastases from occult mammary carcinoma: a case report of carcinoma of unknown primary (CUP) Syndrome 68
Cancer screening in HIV-infected patients: early diagnosis in a high-risk population 68
Surgical treatment for congestive heart failure with autologous adult stem cell transplantation 67
The treatment of peritoneal carcinomatosis in elderly patients. 67
A study of endometrial adenocarcinoma treated with tamoxifen by scanning and transmission electron microscopy. 66
Trattamento palliativo dei tumori del retto-sigma mediante elettrocoagulazione endoscopica.” 66
Targeted drugs in small-cell lung cancer 65
Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer 65
A novel HPLC method for the determination of mitoxantrone in pharmaceutical formulations. 64
DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients 64
Myocardial damage pattern in women with breast cancer who underwent chemotherapy: strain polar maps analysis 64
Etoposide, l-leucovorin and fluorouracil (ELF) regimen in metastatic gastric cancer: A phase II study 63
Gemcitabine (GEM) and cisplatin (CIS) in advanced/metastatic transitional cell carcinoma (TCC) of bladder:phase II study 63
VP16, epirubicin and procarbazine in the treatment of advanced non-small-cell lung cancer. 63
ZD 1839 IRESSA IN HEAVILY PRETREATED PATIENTS WITH ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER:ASSESSMENT OF TOLERABILITY AND CLINICAL BENEFIT 63
INFLUENCE OF CYP2C9 POLYMORPHISM IN LUNG CANCER SUSCEPTIBILITY 62
Gemcitabine (GEM) and cisplatin (Cis) in advanced/metastatic transitional cell carcinoma (TCC) of bladder: Phase II study 62
Erlotinib therapy in a patient with non-small-cell lung cancer and brain metastases 62
A randomized factorial trial of sequential doxrubicina and CMF vs CMF and chemoterapy alone vs chemoterapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer 62
One-year follow up assessment of chemotherapy-related vascular toxicity: an arterial stiffness study 62
Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: A phase II study 61
Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: Understanding transforming growth factor-beta role 61
Bleomycin, epirubicin, carboplatin (BECA) in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck 60
Espressione differenziale di un panel di miRNA in tumori cerebrali astrogliali con diverso grado di malignità. 60
Transpersonal integrated interventions to improve quality of life in cancer patients in all stages of disease 59
Antiblastic treatment of advanced cervical carcinoma and its recurrences: assessment of four different polychemotherapies used for a decade. 59
Temozolomide-induced shrinkage of a pituitary carcinoma causing Cushing's disease--report of a case and literature review. 59
Alectinib: A selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer 59
An acute-leukaemia-like picture due to breast carcinoma cells. 58
The treatment of recurrent and metastatic cervical carcinoma. Evaluation of an antiblastic combination of methotrexate-adriamycin-bleomycin (MAB) 58
Analisi dello stato di metilazione del promoter di O6-methylguanine DNA methyltransferase (MGMT) e TMS1/ASC nei gliomi cerebrali diffusi di basso grado: possibili implicazioni cliniche e prognostiche. 58
Phase II study paclitaxel (PTX) and cisplatin (Cis) in advanced and recurrent head&neck cancer 57
Phase II study Paclitaxel (PTX) and Cisplatin (Cis) in advanced and recurrent head and neck cancer 57
A PHASE III RANDOMIZED TRIAL COMPARING THREE PLATINUM-BASED DOUBLETS IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): IMPACT OF PS=2 VS 0 OR 1 AND AGE ³70 VS <70 ON CHEMOTHERAPY OUTCOME 57
Retrospective analiysis of P-STAT6 expression as predictive marker in primary nervous system lymphoma patients assigned to high-dose methotrexate 57
VP16, epirubicin and procarbazine in the treatment of advanced non-small-cell lung cancer. 57
Treatment of advanced and/or metastatic epidermoid carcinoma of the head and neck: an effective combination chemotherapy with bleomycin, methotrexate and ftorafur. 57
Clodronate and radiotherapy for the treatment of osteolysis caused by metastasis of breast carcinoma and non-small cell lung carcinoma. A retrospective study 57
ANALYSES AND DETERMINATION OF LONIDAMINE RELEASE FROM PHARMACEUTICAL FORMULATION. 57
A PHASE II STUDY (21 DAY REGIMEN) OF GEMCITABINE AND CISPLATIN IN TRANSITIONAL CELL CARCINOMA OF BLADDER 57
Left atrial function in patients undergoing chemotherapy: additional value of 2D longitudinal strain 57
A double-blind randomized study comparing intramuscular (i.m.) granisetron with i.m. granisetron plus dexamethasone in the prevention of delayed emesis induced by cisplatin 56
Microvessels density evaluation in human meningiomas: an immunohistochemical investigation by the specific marker for neoangiogenesis CD105 (Endoglin). 56
Endocrine toxicity of immune checkpoint inhibitors (anti-PD-1/PD-L1) in advanced cancer 56
Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors. 55
Sternal metastasis as initial presentation of a unknown rectal cancer 55
Peritoneal carcinomatosis of colorectal origin. 55
Thyroid function, autoimmunity and nodules in hematological malignancies 55
Temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer 55
Effects of synthetic salmon calcitonin in the treatment of bone lesions of the neoplastic type 54
Mechanical dispersion and cardiotoxicity in patients who underwent chemotherapy for breast cancer: an echocardiographic study 54
null 53
Necrotizing fasciitis as a rare complication of osteonecrosis of the jaw in a patient with multiple myeloma treated with lenalidomide: case report and review of the literature. 53
Thyroid hormone autoantibodies: Are they a better marker to detect early thyroid damage in patients with hematologic cancers receiving tyrosine kinase inhibitor or immunoregulatory drug treatments? 53
First Line Chemotherapy with Oral Vinorelbine (oV) in Elderly Hormone-Refractory Prostate Cancer (HRPC) Patients (pts 52
Behavior of serum sialic acid levels at various stages of neoplastic disease 52
90Y-IBRITUMOMAB TIUXETAN CONSOLIDATION AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IMPROVES SURVIVAL OF INTERMEDIATE/HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS NOT RESPONDING ADEQUATELY TO FIRST 52
Pharmacogenomics in non-small-cell lung cancer chemotherapy. 51
PHASE II STUDY PACLITAXEL AND CISPLATIN IN ADVANCED AND RECURRENT HEAD & NECK CANCER 51
ONDANSETRON PLUS DEXAMETHASONE IN THE CONTROL OF HIGH-DOSE CISPLATIN-INDUCED EMESIS 51
La farmacogenomica nei tumori del polmone 51
Severe pulmonary complications after bortezomib treatment for multiple myeloma: An unrecognized pulmonary vasculitis? 51
Gemcitabine as single agent in the treatment of elderly patients with advanced non small cell lung cancer 51
Transpersonal Therapy Combined with Best Supportive Care In Hospice Improve Patient’s Quality of Life and Quality Of Death 51
Unusual relapse of hepatocellular carcinoma 51
Association between XPD 312 single nucleotide polymorphism (SNP) and clinical outcome in stage IIIA-B non-small-cell lung cancer (NSCLC) patients (P) < 59 years (Y) treated with chemotherapy followed by surgery 51
ZD 1839 IRESSA IN HEAVELY PRETREATED PATIENTS WITH ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER (NSCLC) ASSESSMENT OF TOLERABILITY AND THE CLINICAL BENEFIT 50
[(186)Re]HEDP in the palliation of painful bone metastases from cancers otherthan prostate and breast. 50
From the bench to the bed: individualizing treatment in non-small-cell lungcancer 50
Relapsed or refractory extranodal DLBCL treated with lenalidomide: A single center study 50
Venous damage prevention by defibrotide in vinorelbine-treated patients 49
Older people with non small cell lung cancer in clinical stage IIIA and co-morbid conditions - Is curative irradiation feasible? Final results of a prospective study 49
Studio immunoistochimico dei recettori della somatostatina nei meningiomi intracranici: correlazione tra densità microvascolare e proliferazione cellulare. 49
Analysis of multilayer strain and myocardial work in patients undergoing chemotherapy treatment: a 12 months follow-up 49
Mucocutaneous toxicity induced by pegylated liposomal doxorubicin. A single institution, retrospective case series 49
A PHASE II STUDY (21 day regimen) OF GEMCITABINE (Gem) AND CISPLATIN ( Cis) IN ADVANCED/METASTATIC TRANSITIONAL CELL CARCINOMA (TTC) OF BLADDER 48
Totale 6.508
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.785
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.785
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019314 0 0 22 4 165 20 32 11 10 18 21 11
2019/20201.750 277 130 10 126 38 238 221 177 34 212 257 30
2020/20211.607 169 18 337 114 185 170 48 148 64 169 118 67
2021/20221.546 10 222 45 40 59 20 83 61 31 241 268 466
2022/20234.164 311 369 173 286 306 397 61 251 1.809 28 118 55
2023/2024296 83 140 73 0 0 0 0 0 0 0 0 0
Totale 10.914